Recent studies have highlighted the role of the JAK/STAT signalling pathway in chronic skin conditions such as atopic dermatitis, vitiligo, alopecia areata, lichen planus, and various granulomatous disorders like sarcoidosis, necrobiosis lipoidica, and granuloma annulare. Ruxolitinib is a first-generation JAK inhibitor that the US Food and Drug Administration approved for treating intermediate or high-risk myelofibrosis in 2011. Recently, the topical formulation has been approved to manage mild to moderate atopic dermatitis and non-segmental vitiligo in adults. Encouraging results have been demonstrated with topical ruxolitinib in multiple other skin diseases. This review provides a comprehensive analysis of the use of ruxolitinib in dermatological conditions through a PubMed literature search.
No takes yet. Share an insight, caveat, or question.
Saraswat et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: